100th patient joins ChariotMS trial for multiple sclerosis
The trial is testing whether Mavenclad could benefit upper limb movement in MS patients
Read Moreby Jen Brogan | Nov 10, 2023 | News | 0
The trial is testing whether Mavenclad could benefit upper limb movement in MS patients
Read Moreby Jen Brogan | Oct 2, 2023 | News | 0
The study analysed and compared information from 65,000 MS patients
Read Moreby Selina McKee | May 7, 2021 | News | 0
It is hoped that the multi-armed Octopus trial will rapidly speed up development of new treatments
Read Moreby Lucy Parsons | Nov 19, 2020 | News | 0
Trial will evaluate whether Mavenclad can slow the rate of upper limb disability progression
Read Moreby Selina McKee | Apr 22, 2020 | News | 0
Calls to the MS helpline have increased significantly
Read Moreby Anna Smith | Feb 18, 2020 | News | 0
The Society hopes that the new online function will relieve pressure on healthcare professionals, and could result in significant cost savings for the NHS as demand for the face-to-face programme lessens.
Read Moreby Anna Smith | Oct 10, 2019 | News | 0
The Stop MS Appeal aims to raise the funds over ten years to find treatments for everyone living with the progressive, immune-mediated disorder.
Read Moreby Anna Smith | Jul 30, 2019 | News | 0
The money will go to a new UK ‘digital brain bank’, Europe’s largest brain and tissue bank, based in London.
Read Moreby Selina McKee | Sep 10, 2018 | News | 0
The MS Society has launched a petition imploring the National Institute for Health and Care Excellence, NHS England and Roche to come to an agreement on NHS availability of Ocrevus for primary progressive multiple sclerosis (PPMS).
Read Moreby Selina McKee | May 9, 2017 | News | 0
Researchers have kicked off a £6 million trial investigating the potential of simvastatin as a treatment for multiple sclerosis.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479